All In Biotech

Drug Trial Radar · NCT06992687

A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors

A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0052 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 1, 2024

Primary completion

Sep 30, 2025

Study completion Nov 30, 2025

Sponsor

Sponsor type
Industry
Collaborators
Peking University Cancer Hospital & Institute; Zhejiang Cancer Hospital; Shandong Cancer Hospital and Institute; Hunan Cancer Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; The Second Affiliated Hospital of Harbin Medical University; Huazhong University of Science and Technology
First posted
May 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors

Conditions

  • Solid Tumors

Interventions

  • HB0052 InjectionDrug

    An antibody- drug conjugate (ADC) that targets CD73 with SN38 as the payload

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: Up to 12 Months
  2. MTDTime frame: Up to 24 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.